Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats
Open accessThe DOI matches its Crossref record.
Abstract
The pharmacokinetics and tissue distribution of two amphotericin B dosage forms were compared in rats. A novel lipid-based colloidal delivery system for amphotericin B (Amphotericin B Colloidal Dispersion [ABCD]) which reduces the toxicity of amphotericin B in animals was compared with a conventional micellar formulation. Male Sprague-Dawley rats received a single intravenous injection of 1.0 mg of ABCD, 5.0 mg of ABCD, or 1.0 mg of micellar amphotericin B per kg. Plasma and tissue samples were obtained at 0.5 to 96 h after dosing and analyzed for amphotericin B by high-pressure liquid chromatography. Animals receiving ABCD demonstrated reduced peak levels in plasma, a three- to sevenfold reduction in amphotericin B delivery to the kidneys (the major target organ for toxicity), and prolonged residence time compared with those receiving the micellar formulation. In contrast, amphotericin B concentrations in the liver were two- to threefold higher with ABCD than with the micellar formulation: nearly 100% of the amphotericin B administered as ABCD was recovered from the liver 30 min after dosing. These results suggest that the colloidal particles of ABCD are taken up by the liver, which then acts as a reservoir of amphotericin B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tissue Penetration of Antifungal Agents
Felton, T., Troke, P. F., & Hope, W. W. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-13 · Cited by 426
Amphotericin B: time for a new “gold standard”
Saravolatz, L. D., Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H., & Cohen, S. H. (2003) · Clinical Infectious Diseases · doi:10.1086/376634 · Cited by 406
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani, M., & Farhoudi, R. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s146521 · Cited by 355
Carrier effects on biological activity of amphotericin B
Brajtburg, J., & Bolard, J. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.512 · Cited by 310
Amphotericin B Formulations and Drug Targeting
Torrado, J. J., Espada, R., Ballesteros, M. P., & Torrado-Santiago, S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21179 · Cited by 299
Liposomal and Lipid Formulations of Amphotericin B: Clinical Pharmacokinetics
Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. J. M., & Crommelin, D. J. A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223040-00004 · Cited by 274
Recent Approaches to Antifungal Therapy for Invasive Mycoses
Mathew, B. P., & Nath, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800353 · Cited by 105
Scaling basic toxicokinetic parameters from rat to man.
Bachmann, K., Pardoe, D., & White, D. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.96104400 · Cited by 90
Metadata
- Authors
- Fielding, R. M., Smith, P. C., Wang, L. H., Porter, J., & Guo, L. S.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1991-06
- Volume
- 35
- Issue
- 6
- Pages
- 1208-1213
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2000163153
- Cited by
- 117
- References
- 0
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.